Antidepressant Treatment Outcome Depends on the Quality of the Living Environment: A Pre-Clinical Investigation in Mice by Igor, Branchi et al.
Antidepressant Treatment Outcome Depends on the
Quality of the Living Environment: A Pre-Clinical
Investigation in Mice
Igor Branchi1,2*, Sara Santarelli1, Sara Capoccia1, Silvia Poggini1, Ivana D’Andrea3, Francesca Cirulli1,
Enrico Alleva1
1Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita`, Rome, Italy, 2 Institute of Anatomy, University of Zurich, Zurich, Switzerland, 3Department of
Neuro and Cardiovascular Pathology, Neuromed Insitute – Technology Park, Pozzilli, Italy
Abstract
Antidepressants represent the standard treatment for major depression. However, their efficacy is variable and incomplete.
A growing number of studies suggest that the environment plays a major role in determining the efficacy of these drugs,
specifically of selective serotonin reuptake inhibitors (SSRI). A recent hypothesis posits that the increase in serotonin levels
induced by SSRI may not affect mood per se, but enhances neural plasticity and, consequently, renders the individual more
susceptible to the influence of the environment. Thus, SSRI administration in a favorable environment would lead to a
reduction of symptoms, while in a stressful environment might lead to a worse prognosis. To test this hypothesis, we
treated C57BL/6 adult male mice with chronic fluoxetine while exposing them to either (i) an enriched environment, after
exposure to a chronic stress period aimed at inducing a depression-like phenotype, or (ii) a stressful environment.
Anhedonia, brain BDNF and circulating corticosterone levels, considered endophenotypes of depression, were investigated.
Mice treated with fluoxetine in an enriched condition improved their depression-like phenotype compared to controls,
displaying higher saccharin preference, higher brain BDNF levels and reduced corticosterone levels. By contrast, when
chronic fluoxetine administration occurred in a stressful condition, mice showed a more distinct worsening of the
depression-like profile, displaying a faster decrease of saccharin preference, lower brain BDNF levels and increased
corticosterone levels. Our findings suggest that the effect of SSRI on depression-like phenotypes in mice is not determined
by the drug per se but is induced by the drug and driven by the environment. These findings may be helpful to explain
variable effects of SSRI found in clinical practice and to device strategies aimed at enhancing their efficacy by means of
controlling environmental conditions.
Citation: Branchi I, Santarelli S, Capoccia S, Poggini S, D’Andrea I, et al. (2013) Antidepressant Treatment Outcome Depends on the Quality of the Living
Environment: A Pre-Clinical Investigation in Mice. PLoS ONE 8(4): e62226. doi:10.1371/journal.pone.0062226
Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan
Received January 28, 2013; Accepted March 19, 2013; Published April 30, 2013
Copyright:  2013 Branchi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for this study was provided by the Italian Ministry of Health, Ricerca Finalizzata 2009, Fasc. 12AF to FC and Ricerca Finalizzata 2008, Fasc. 10BF
to EA, and Fondazione Veronesi 2012 to FC. IB was supported by EU, Marie Curie IEF fellowship for Experienced Researcher n: 302881 - Acronym: MODELMOOD.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: branchi@iss.it
Introduction
Major depression is a chronic, recurring and potentially life-
threatening illness that affects up to 10% of the population across
the globe. It is the leading cause of years lost owing to disability
worldwide and the third overall contributor to the worldwide
burden of disease (projected to be the biggest contributor by 2030)
[1]. In the USA, the annual cost of depression is estimated at $ 83
billion [2] while in Europe, it is estimated over J 120 billion [3].
Antidepressants represent the current standard treatment for
major depression. However, their efficacy is variable and
incomplete: 60–70% of depressed patients do not experience
remission and 30–40% do not show a significant response [4].
Recent publications have also cast doubts about antidepressant
efficacy [5,6,7], claiming that when a comprehensive analysis of all
trials available is performed, their effects are not significantly
different from placebo [8,9,10,11]. These studies have been widely
criticized [12,13] and most psychiatrists believe that antidepres-
sants work and therefore prescribe them to patients [13]. Thus, a
debate on antidepressant efficacy is open.
A new theoretical framework proposing the quality of the
environment as the critical intervening factor determining the
therapeutic efficacy of selective serotonin reuptake inhibitors
(SSRIs) has been recently developed [14]. Such hypothesis, named
the undirected susceptibility to change model, posits that the
capability of the individual to change its behavior according to the
environment depends on neural plasticity, which in turn is
controlled by serotonin. Consequently, the increase in serotonin
levels induced by SSRIs might not affect mood per se but enhance
neural plasticity which -- acting as a catalyzer – renders the
individual more susceptible to the influence of the environment.
Therefore, treatment in a favorable environment, such as a high
socioeconomic status [15], leads to a reduction of symptoms; by
contrast, treatment in a stressful environment leads to a worse
prognosis.
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In support to this hypothesis, a number of indirect evidences
both from clinical and preclinical studies indicate that increased
serotonin levels lead to greater brain plasticity and higher
susceptibility to environmental inputs [14,16,17,18,19,20]. For
instance, clinical studies investigating variations of the serotonin-
transporter–linked polymorphic region, 5-HTTLPR, found that
individuals bearing the s/s variant, associated with higher brain
extracellular levels of serotonin, show an enhanced behavioral
plasticity and susceptibility to the influence of the environment
compared to individuals bearing the l/l variant [16,21,22]. With
regard to antidepressant treatment, preliminary evidence shows
that the likelihood to commit suicide is higher when patients come
from a poor socioeconomic background [23]. By contrast, SSRI
are more effective in patients with high socioeconomic status [4].
The main aim of this study was to test the potential double
outcome of SSRI treatment and to investigate whether it depends
on the quality of the environment. To this purpose, we chronically
treated mice with fluoxetine (FLX) while exposing them to either
(i) an enriched condition, after a 24-days exposure to stress aimed
at inducing a depression-like phenotype (Fig. 1A), or to (ii) a
stressful condition, following exposure to enrichment (Fig. 1B).
Mice underwent a switch in the quality of the environment to
highlight its relevance in determining the effects of antidepressant
administration. Three endpoints, considered endophenotypes of
major depression, have been investigated: (a) anhedonia – i.e., loss
of interest or pleasure in normal activities -- one of the nine
symptoms defined by the Diagnostic and Statistic Manual (DSM-IV-
TR) for major depression, which has been successfully translated
in mice [24]; (b) BDNF levels, reported to be reduced in depressed
patients [25,26] and increased by antidepressant administration
both in humans [27,28] and in animal models [29,30,31]; (c)
corticosterone levels, resulting from the activity of the hypothal-
amus-pituitary-adrenals axis (HPA), found to be altered in
depressed patients [32,33,34] and in animal models [35].
In line with the undirected susceptibility to change model, our
prediction was that, FLX-treated mice would be more sensitive to
the quality of the environment, displaying both a better recovery
from a depression-like profile, when exposed to an enriched
condition, and a faster worsening when exposed to a stressful
condition. In order to control for the role of the environment in
driving FLX effects, further experimental groups of mice were
treated while exposed to a constant environment, either enriched
or stressful (Fig. 1C and 1D). In this case, we predicted that the
lack of switch in the quality of the environment would lead to no
modification in depression-like endpoints, with overlapping results
in the FLX-treated and the control group.
Materials and Methods
Animals, Intellicages and enriched condition
All experiments were conducted in conformity with European
Communities Council Directive 2010/63 and the Italian Decreto
L.vo 116/92. The protocol was approved by the Italian Ministry
of Health (Permit number 58/2012-B). All efforts were made to
minimize suffering. In particular, the principles of Reduction and
Refinement (i.e., the ‘three Rs’) have been applied to all
experiments. C57BL/6 male mice 12–15 week old were used
and kept under 12-hour light-dark cycle at 22–25 uC. Animals
were housed in the Intellicage system (NewBehavior AG, Zu¨rich,
Switzerland), which is an apparatus for automatic monitoring of
mouse behavior. This system is able to score the behavior of each
individual living in a social group since each one is identified by a
subcutaneous transponder. It consists of two large acrylic cage
(20.5 cm high, 58 cm640 cm at the top and 55 cm637.5 cm at
the base, Model 2000 Tecniplast, Buguggiate, VA, Italy), each one
Figure 1. Experimental design. (A,B) Environmental switch protocols. (A) Fluoxetine treatment in an enriched condition after exposure to stress.
(B) Fluoxetine treatment in a stressful condition, after exposure to enrichment. (C,D) Constant environment protocols. (C) Fluoxetine treatment in a
stressful condition, after exposure to stress. (D) Fluoxetine treatment in an enriched condition, after exposure to enrichment.
doi:10.1371/journal.pone.0062226.g001
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with 4 walls separating each corner from the center so that they
form 4 identical chambers to which mice have free access by
entering a front hole (for a detailed description of the system see
[36,37,38]). Intellicages collect data about (i) number and duration
of visits in the four corners (exploratory activity); (ii) number,
duration and side (right or left) of nosepokes; (iii) number, duration
and side (right or left) of licks.
For the entire duration of each experiment, animals were
housed in two Intellicages, balancing group composition. Five days
before being moved to the Intellicages, each animal was injected
with a subcutaneous transponder (T-IS 8010 FDX-B; Datamars
SA, Switzerland). Food was freely available. The animals have
been gradually habituated to the Intellicage environment during a
16-days period. During such period, the animals were habituated
also to the 0.1% of saccharin solution. On the last two days of the
habituation period, baseline preference for saccharin over water in
the enriched environment provided by the Intellicages was
determined.
The Intellicage environment consists in an enrichment condi-
tion because mice are socially housed and are exposed to Plexiglas
shelters of different colors and shapes (three red transparent
Tecniplast plastic nest boxes and four white opaque boxes), and to
tissue paper. New paper was provided each 5 days and the plastic
shelters were cleaned and placed back each week.
Saccharin preference
To assess saccharin preference, in each corner of the Intellicage,
2 bottles were present, one containing tap water and the other
containing 0.1 % saccharin solution; both were freely available
24/24 h. Water and saccharin solution were substituted every day.
The position of water and saccharin in each corner was
counterbalanced across the 4 corners. Saccharin preference was
determined as follows: (saccharin solution consumed/saccharin
solution consumed +water consumed)6100.
Stress condition
Stress condition consisted in exposing everyday mice to a
different stressful procedure, randomly chosen among restraint,
social stress or forced swim. Exposing mice to different stressful
procedures was used to prevent habituation.
Restraint procedure was performed exposing animals to a
60 min restraint in a ventilated 50 ml Falcon tube (provided by
hand-made holes on the tube surface). Social stress consisted in
modifying social groups [36]. In particular, social group in each
cage was modified so that 3 mice (2 vehicle and 1 FLX or 1 vehicle
and 2 FLX) were moved from Intellicage 1 to Intellicage 2 and
vice versa. This procedure forces animals to reorganize their social
structure, imposing them a stressful condition. For the forced swim
stress, each experimental subject was gently placed into a
cylindrical glass container (20cm diameter, 40cm height), filled
with 25cm of water at a temperature of 2161uC for 10 min with a
dim light illumination (1 lux). When removed from the water, the
mouse was allowed to dry for 5 min under red light.
Fluoxetine treatment
Fluoxetine (Biomol International, LP, USA) was dissolved in
water and in saccharin solution and delivered ad libitum in the
drinking bottles for 3 weeks. Compared to administration by
injection, this method allows to avoid the stress due to the
manipulation. The solutions were prepared according to the
average weight and daily water consumption previously assessed of
the mice, in order to provide an average daily intake of 10 mg/kg.
The amount of water drunken by FLX-treated mice and controls
was equivalent. The total amount of water and sweet solution (i.e.
with saccharin) drunk by treated mice allowed to reach an effective
FLX serum level around 150 ng/ml, as shown in previous studies
[39]. Bottles were wrapped in tin foil to protect the substance from
light. Solution was made fresh every day.
Corticosterone levels
Corticosterone levels were measured in all subjects before and
after the chronic stress procedure at baseline (i.e., no exposure to
acute stress). Blood was collected from the tail 1 hr before lights
on. The bleeding procedure consisted in a small and superficial cut
in the tail. Blood samples were collected individually in potassium–
EDTA coated 10 ml tubes (1.6 mg EDTA/ml blood; Sarstedt,
Germany). All samples were kept on ice and later centrifuged at
3000 rpm for 15 min at +4uC. Blood plasma was transferred to
Eppendorf tubes for corticosterone determination and stored at
220uC until further analysis. Corticosterone was measured using a
commercially available radio-immunoassay (RIA) kit containing
125iodine labeled corticosterone (MP Biomedicals Inc., CA, USA).
Vials were counted for 2 min in a gamma-scintillation counter
(Packard Minaxi Gamma counter, Series 5000). Sensitivity of the
assay was 0.125 mg/dl, inter- and intra-assay variation was less
than 10% and 5%, respectively. Because of the asymmetric
distribution, the logarithmic transformation was implemented.
BDNF levels
Brains were collected 6 hrs after lights off and on the last day of
the treatment period. The concentrations of BDNF were
measured in the hippocampus and hypothalamus by an ELISA
kit (BDNF Emax ImmunoAssay System number G6891, Promega,
Madison, WI) according to the instructions of the manufacturer.
Tissues were homogenized in the kit calibration buffer and
centrifuged. The brain tissues were homogenized with ultrasonica-
tion in extraction buffer 0.2% Triton X-100. Briefly, 96-well
immunoplates were coated with 100 microl per well of monoclonal
anti-mouse-BDNF antibody. After an overnight incubation at
48C, the plates were washed three times with wash buffer and the
samples were incubated in the coated wells (100 microl each) for
2 hr at room temperature with shaking. After an additional five
washes the immobilized antigen was incubated with an antihuman
BDNF antibody for 2 hr at room temperature with shaking. The
plates were washed again with wash buffer, and then incubated
with an anti-IgY HRP for 1 hr at room temperature. After
another wash, the plates were incubated with a TMB/peroxidase
substrate solution for 15 min and then phosphoric acid 1 M (100
microl/well) was added to the wells. The colorimetric reaction
product was measured at 450 nm using a microplate reader
(Dynatech MR 5000, PBI International, Temecula, CA). BDNF
concentrations were determined, from the regression line for the
BDNF standard (rangeJ 7.8– 500 pg/ml purified mouse BDNF)
incubated under similar conditions in each assay. The sensitivity of
the assay was about 15 pg/g of BDNF and cross-reactivity with
other related neurotrophic factors (NGF, Neurotrophin-3 and
Neurotrophin-4) was ,3%. All assays were carried out in
duplicate.
Treatment in enriched condition, after exposure to stress
Mice underwent a 24-days stress period consisting in random
exposure to different stressful conditions (i.e. restraint stress, social
stress and forced swim stress). Afterwards, mice were exposed for
21 days to the enriched environment provided by the Intellicages
while administered with FLX or vehicle (Fig. 1A). The preference
to saccharin was monitored on days 1-3, 8-10, 15-17, 22-24 during
the stress period and on days 1-2, 5-6, 9-10, 20-21 during the
treatment period,. CORT levels were measured before stress
Fluoxetine Outcome Is Environment Dependent
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e62226
exposure, immediately before drug administration (i.e. at the end
of the stress exposure) and immediately after the drug adminis-
tration (after 21 days). BDNF levels were measured on the last day
of the treatment period.
Treatment in stressful condition, after exposure to
enrichment
After exposure to the enriched environment provided by the
Intellicages, animals underwent a 24- days stress period while
administered with FLX or vehicle (Fig. 1B). Saccharin preference
was determined on days 1–3, 8–10, 15–17, 22–24 during the 24-
days stress period. CORT levels were measured on the day before
and on the last day of the treatment period. BDNF levels were
measured at the end of the treatment period.
Treatment in stressful condition, after exposure to stress
Mice underwent a 24-days stress period. Afterwards, they were
exposed to a second stress period (21 days), while administered
with FLX or vehicle (Fig. 1C). Preference for saccharin solution
was scored on the last two days before the 24-days stress period, on
the last two days of the 24-days stress period and on the last two
days of the treatment period. CORT levels were measured on the
day before and the last day of the 24-days stress period and at the
end of the treatment period. BDNF levels were measured on the
last day of the treatment period.
Treatment in enriched condition, after exposure to
enrichment
After exposure to the enriched environment provided by the
Intellicages, mice have been exposed to a second enrichment
period (24 days) while treated with FLX or vehicle (Fig. 1D).
Preference for saccharin solution was scored on the last two days
before the treatment period and on the last two days of the
treatment period. CORT levels were measured at the end of the
habituation period and at the end of the treatment period. BDNF
levels were measured on the last day of the treatment period.
Statistical analysis
All data were analyzed with ANOVAs, considering treatment
(vehicle vs. FLX) as between-subject variables and subject as a
random factor nested within treatment; time (day) as repeated
measures within subjects. Post hoc comparisons were performed
using the Tukey’s HSD test (statistical software Statview II, Abacus
Concepts, CA, USA).
Results
Treatment in enriched condition, after exposure to stress
Saccharin preference. During exposure to the enrichment,
the anhedonic profile was significantly affected by the treatment
[F(1,14) = 4.772, p = 0.0464; n = 16 for each group]. In particular,
FLX mice showed a significant preference for the saccharin
solution compared to controls (Fig. 2). During the stress exposure,
both groups of mice showed an overlapping significant reduction
of their preference for saccharin solution [F(6,84) = 2.933,
p = 0.0120]. Before the stress period, anhedonic levels were equal
in the two groups.
Brain derived neurotrophic factor. At the end of the
treatment period, BDNF levels in the hippocampus (vehicle: n = 5;
FLX: n = 5) and hypothalamus (vehicle: n = 6; FLX: n = 6) have
been investigated. A significant increase in BDNF levels has been
found in both brain areas in FLX mice compared to vehicle
[hippocampus: F(1,8) = 5.499, p = 0.0478; hypothalamus:
F(1,10) = 16.982, p = 0.0021; Fig. 3].
Corticosterone levels. Prior to the exposure to stress and
immediately before and after treatment -- i.e., at the beginning
and at the end of enriched condition –– corticosterone levels were
measured (vehicle: n = 7; FLX: n = 6). When analyzing the
differences between corticosterone levels before and after the 24-
days stress period and before and after the treatment period, the
interaction treatment x repeated measure missed statistical
significance [F(1,11) = 3.941, p = 0.0726]. However, post-hoc anal-
ysis revealed that, during the treatment period, FLX mice
displayed a significantly more marked decrease in corticosterone
levels compared to vehicle (p,0.05; Fig. 3).
Treatment in stressful condition, after exposure to
enrichment
Saccharin preference. During treatment in stress condition,
the anhedonic profile differed in FLX mice vs. vehicle
[F(1,11) = 7.410, p = 0.0199; vehicle: n = 7; FLX: n = 6]. Contrary
to the enriched condition, FLX mice showed a faster and more
marked reduction of preference for the saccharin solution
compared to control mice (Fig. 4). In particular, the significant
interaction between treatment and repeated measure
[F(3,33) = 2.928, p = 0.0481] indicates that the difference between
the two groups increased during the treatment, as shown by the
post-hoc analysis (days 15-17: p,0.05; days 21-24: p,0.01). Pre-
stress levels were equal in the two groups.
The effect of the combination of stress and FLX administration
has been replicated in a naı¨ve batch of animals (data not shown).
Also in this case, FLX mice showed a faster and more marked
reduction of saccharin preference [F(1,13) = 5.053, p = 0.0426;
vehicle: n = 7; FLX: n = 8]. Though the treatment x repeated
measure interaction was not significant, post hoc analysis revealed a
significant difference between the two groups at the end of
treatment (p,0.05).
Brain derived neurotrophic factor. At the end of the
treatment period, BDNF levels in the hippocampus (vehicle: n = 6;
FLX: n = 5) and hypothalamus (vehicle: n = 5; FLX: n = 4) of the
experimental subjects have been investigated. A significant
decrease was found in both brain areas of FLX mice compared
to vehicle [hippocampus: F(1,9) = 8.846, p = 0.0156; hypothala-
mus: F(1,7) = 4.290, p = 0.0213; Fig. 5].
Figure 2. Saccharin preference during fluoxetine treatment in
an enriched condition after exposure to stress. Stress exposure
reduced saccharin preference in both groups of mice. Afterwards,
fluoxetine-treated mice showed a significantly higher preference for the
saccharin solution compared to control mice. # indicates p= 0.0120
and * indicates p= 0.0464, vs. vehicle group. Data are means 6 S.E.M.
doi:10.1371/journal.pone.0062226.g002
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Corticosterone levels. At the beginning and at the end of
the treatment period, corticosterone levels have been evaluated
(vehicle: n = 7; FLX: n = 6). When analyzing the differences
between levels before and after the treatment period, a significant
increase in corticosterone levels in FLX mice compared to vehicle
was found [F(1,11) = 17.018, p = 0.0017; Fig. 5].
Treatment in stressful condition, after exposure to stress
Saccharin preference. At the end of the treatment period,
FLX and control mice did not differ in saccharin preference
[F(1,34) = 0.225, p = 0.6383; vehicle: n = 19; FLX: n = 17]. Both
groups showed a preference around 60–70%. Preference levels
were significantly reduced by exposure to the 24-days stress period
[F(1,34) = 15.653, p = 0.0004; Fig. 6A].
Brain derived neurotrophic factor. BDNF levels in the
hippocampus and hypothalamus (vehicle: n = 11; FLX: n = 8) have
been investigated at the end of the treatment period. No difference
in BDNF levels between the two groups was found in the two brain
areas [respectively, Fs(1,17) = 0.429, 2.845, ps = 0.5213, 0.1099;
Fig 6B and 6C].
Corticosterone levels. The analysis performed on the
differences in corticosterone levels measured before and after the
exposure to the 24-day stress period and before and after the
treatment period showed a significant treatment x repeated
measure interaction [F(1,14) = 6.548, p = 0.0227; vehicle: n = 7;
FLX: n = 9]. Post-hoc analysis revealed that, during the treatment
period, FLX mice displayed a significant increase in corticosterone
levels compared to vehicle (p,0.05; Fig. 6D).
Treatment in enriched condition, after exposure to
enrichment
Saccharin preference. At the end of treatment in enriched
conditions, the anhedonic profile of FLX and control mice did not
differ [F(1,11) = 0.002, p = 0.9642; vehicle: n = 11; FLX: n = 11].
Both groups showed a very high preference for the saccharin
solution, around 100% (Fig. 6E).
Brain derived neurotrophic factor. BDNF levels in the
hippocampus (vehicle: n = 8; FLX: n = 11) and hypothalamus
(vehicle: n = 8; FLX: n = 11) have been investigated at the end of
the treatment period. No difference in BDNF levels has been
found in both brain areas of FLX mice compared to vehicle
[respectively: Fs(1,17) = 0.386, ps = 0.5428, 0.4326; Fig. 6F and
6G].
Corticosterone levels. The analysis of the differences in
corticosterone levels before and at the end of treatment revealed a
significant treatment x repeated measure interaction
[F(1,14) = 17.989, p = 0.008; vehicle: n = 7; FLX: n = 9]. Post-hoc
analysis showed that, during the treatment period, FLX mice
displayed a significant decrease in corticosterone levels compared
to vehicle (p,0.05; Fig. 6H).
Discussion
Our results show that, after a period of stress, which induces a
depression-like phenotype, mice exposed to a favorable environ-
ment, such as enrichment, recovered when treated with FLX,
displaying reduced anhedonia, higher brain BDNF levels and
lower corticosterone levels compared to controls. By contrast,
when chronic FLX administration occurred in a stressful
condition, mice showed a more pronounced worsening of
behavioral and neuroendocrine endpoints indicative of a depres-
Figure 3. BDNF and corticosterone levels in mice in an enriched
condition after exposure to stress. Following the 21 days of
recovery, fluoxetine mice showed a significant increase of hippocampal
and hypothalamic BDNF levels as well as significantly more marked
decrease in corticosterone levels compared to controls. * and **
indicate, respectively, p,0.05 and 0.01 vs. vehicle group. Delta (D)
values were calculated comparing data obtained on the day before
treatment and on last day of treatment. Data are means 6 S.E.M.
doi:10.1371/journal.pone.0062226.g003
Figure 4. Anhedonic profile during fluoxetine treatment in a
stressful condition after exposure to enrichment. When social
stress was imposed during treatment, fluoxetine-treated mice showed a
faster and more marked reduction of preference for the saccharin
solution compared to control mice. # indicates p=0.0199, * and **
indicate, respectively, p,0.05 and 0.01 vs. vehicle group. Data are
means 6 S.E.M.
doi:10.1371/journal.pone.0062226.g004
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sion-like phenotype. Specifically, FLX-treated mice showed a
faster decrease of saccharin preference, already evident after two
weeks of treatment, and had lower brain BDNF levels and
increased corticosterone levels. When treatment was administered
in a constant environment, FLX did not affect the depression-like
phenotype and the two experimental groups showed overlapping
results, with the exception of corticosterone levels. Concerning the
latter parameter, FLX increased levels of this hormone in a
stressful condition, while reducing it in an enriched environment.
Results concerning the effects of FLX in an enriched condition,
after exposure to stress, are in line with the expected effects of
antidepressants [40]. Indeed, treatment allowed a recovery from
the depression-like phenotype, improving the three endpoints
considered symptoms/biomarkers of the psychopathology. How-
ever, these effects cannot be ascribed only to drug action per se, but
are due to the combination of treatment and the environmental
context. In fact, different results are obtained when the antide-
pressant is administered in a different environmental context. In
particular, results indicate that a switch from an enriched to a
stressful environment increases anhedonia in control mice, in line
with the literature [41,42] and that FLX amplifies such effect. The
latter finding, replicated twice in the present study, is not in line
with some previous data indicating an increased preference for the
sweet solution following SSRI administration [43,44]. Nonethe-
less, other data in the literature show increased anhedonia
following SSRI administration [45,46,47,48]. A similar picture
has been reported for the effects of SSRIs administered in a
stressful condition on BDNF and corticosterone levels. Indeed, the
reduction of BDNF levels here reported is incongruent with some
studies showing that SSRIs increase levels of this neurotrophin
[29,43]. However, other studies found that chronic FLX has no
effect [49,50,51] or even reduces BDNF levels
[52,53,54,55,56,57]. With regard to HPA axis activity, though
some studies described a reduction of corticosterone levels [58,59],
mainly mediated by an increased expression of glucocorticoid
receptors [60], others have indicated opposite effects [61,62]. The
inverted relationship between corticosterone and BDNF levels
found in mice exposed to either the enriched or the stressful
condition has already been reported [63,64,65]. In addition, the
association between the low BDNF levels and the anhedonic
profile, indicative of a depression-like phenotype, is in line with
studies in patients [26,27,28]. The lack of FLX effects on saccharin
preference and BDNF levels in constant environmental conditions
confirms that effects of the drug are driven by the environment.
The significant change in corticosterone levels, even in a constant
environment, on the one hand suggests that this parameter is more
sensitive than anhedonia and BDNF to the effects of the
combination of the drug and the environment, being altered even
after a period of habituation, on the other, confirms that FLX
treatment amplifies the effects of the environment, either
supportive or adverse. Overall, the results here described are in
line and support the undirected susceptibility to change model
positing that an enhancement of the serotonin system increases the
individual’s plasticity and, thus, the sensitivity to the environmen-
tal context [14].
Though very few studies on patients have investigated the
influence of the environment on antidepressant action, their
findings show that living conditions, e.g. socioeconomic status,
modulate the effects of antidepressants. In line with the present
results, low-income people who suffer from depression are less
likely to respond to antidepressant treatment than those in middle-
and high-income groups [23,66]. In addition, findings from the
Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study, which investigated the response to the SSRI
citalopram in over 4000 depressed patients, showed that
participants who were Caucasian, female, employed or had higher
levels of education or income had higher remission rates. By
contrast, longer index episodes, more concurrent psychiatric
disorders, more general medical disorders and lower baseline
function and quality of life were associated with lower remission
rates [4]. The relevance of social inequalities in affecting
antidepressant treatment outcome has been highlighted by the
World Health Organization [67].
Recently, doubts have been brought about on antidepressant
efficacy [5,6,7,8]. In particular, the studies by Irvin Kirsch showed
that, compared to placebos, different antidepressants have a very
limited effect, possibly of no clinical significance. In addition,
Kirsch speculated that even such a limited effect might be an
artifact due to the fact that side effects enable patients to guess that
they are receiving the active drug, making them more likely to
report an improvement in symptoms [11]. In line with this
hypothesis, in trials employing ‘‘active’’ placebos causing side, no
differential effects with drug treatment were found [10]. However,
most psychiatrists, based on their own clinical experience, believe
Figure 5. BDNF and corticosterone levels in mice in a stressful
conditions after exposure to enrichment. Following social stress
mice treated with fluoxetine showed reduced BDNF levels in both
hippocampus and hypothalamus compared to control mice. Plasmatic
corticosterone levels resulted increased in fluoxetine mice as shown by
the statistically significant difference between levels before and after
the treatment period. ** indicates p,0.01 vs. vehicle group. Delta (D)
values were calculated comparing data obtained on the day before
treatment and on last day of treatment. Data are means 6 S.E.M.
doi:10.1371/journal.pone.0062226.g005
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that antidepressants work and thus prescribe them to depressed
patients [12,13,68]. Indeed, antidepressants are among the most
prescribed drugs in western countries [69].
Data from this study provide an explanation for the variability
found in clinical trials [70,71] and for the fact that an effective
treatment may result ineffective. In clinical trials the environment
in which patients live is not -- or is only partially – controlled. As a
consequence, the proportion of patients living in a supportive or,
vice versa, in a stressful environment is likely to change from trial
to trial: when such proportions are approximately equal, an
absence of effect would be reported, because the beneficial and
harmful effects of SSRI treatment may compensate each other;
otherwise, when the number of patients exposed to a supportive or
a stressful environment is not balanced, a positive or negative
treatment outcome may be found. The undirected susceptibility to
change model also justifies the lack of a difference in the effects
between high and low doses [8] and explains other incongruities
about SSRI effects reported in the literature, such as the high
placebo response rate and the efficacy of treatments based on
opposite mechanisms of action (e.g., SSRI vs. serotonin selective
reuptake enhancers; for a detailed description, see [14]).
Some limitations in our interpretation of the experimental
results need to be underlined. First, part of the assumptions is
mainly based on results collected using animal studies. Therefore,
ad hoc clinical and epidemiological studies are needed to further
test the validity of our hypothesis. In addition, the serotonergic
system was considered as acting as a whole, not taking into
account its high molecular complexity and its wide range of effects,
such as those on food intake or circadian rhythm. Finally, further
studies involving experimental groups exposed to a standard,
neither enriched nor stressful, environment are warranted to better
describe the interplay between treatment and quality of the
environment.
In conclusion, our findings suggest that SSRI administration
does have an effect. However, such effect is not determined by the
drug per se but is induced by the drug and driven by the
environment. Such critical role of the environment is corroborated
by our results showing that FLX treatment has limited effects
when administered in constant environmental conditions. This
view may be helpful to better understand SSRI effects and
selectively enhance their efficacy through the control of environ-
mental conditions in patients. This could be achieved by training
patients to cope with harsh environments, for instance through
cognitive behavioral therapy [72], since it is unlikely that people
can rapidly and effectively change their living milieu. The cost of
this approach is limited since no new psychoactive molecules need
to be developed, while the benefits for the patients could be
substantial.
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Figure 6. Results of experiments investigating the effects of fluoxetine treatment in a constant environment. (A,B,C,D) Fluoxetine
treatment in a stressful condition, after exposure to stress. (A) Saccharin preference: exposure to stress before treatment significantly reduced
saccharin preference. The following fluoxetine treatment administered in stressful conditions did not modify the anhedonic response. (B)
Hippocampal and (C) hypothalamic BDNF levels: no difference between the two groups has been found. (D) Corticosterone levels. Fluoxetine mice
showed a significant increase in corticosterone levels compared to vehicle. (E,F,G,H) Fluoxetine treatment in an enriched condition, after exposure to
enrichment. (E) Saccharin preference: no difference between the two groups has been found. (F) Hippocampal and (G) hypothalamic BDNF levels: no
difference between the two groups has been found. (H) Corticosterone levels: fluoxetine mice showed a significant decrease in corticosterone levels
compared to vehicle. * indicates p,0.05 vs. vehicle group. # indicates p,0.01 vs. baseline level. Delta (D) values were calculated comparing data
obtained on the day before treatment and on last day of treatment. Data are means 6 S.E.M.
doi:10.1371/journal.pone.0062226.g006
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